AbbVie ABBV announced the submission of regulatory applications to the FDA and European Medicines Agency (EMA) seeking approval of its drug Skyrizi (risankizumab) for a new indication, moderately to ...

- Submissions supported by two Phase 3 studies in patients with active psoriatic arthritis in which SKYRIZI demonstrated improved skin and joint symptoms and physical function, with a greater ...

It looks like AbbVie has the trial win it was hoping for to unlock the psoriasis market for its recently-approved psoriasis therapy Skyrizi. The head-to-head study pitted IL-23 antagonist Skyrizi ...

AbbVie has big plans to grow sales for Humira follow-ups Skyrizi and upadacitinib. Early into its Skyrizi launch for psoriasis, the company has offered discounts on its megablockbuster Humira to ...

When AbbVie won FDA approval for its next-generation immunology drugs Skyrizi and Rinvoq in 2019, the company had high hopes that the drugs could fill what threatened to be a gaping hole in the top ...

Skyrizi may lead to mild side effects, including headaches, fatigue, injection site reactions, and upper respiratory infections. Serious side effects, such as an increased risk of infections, may ...

AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used Stelara in a head-to-head trial.

Skyrizi (risankizumab-rzaa) is a prescription injection used for treating plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Skyrizi is typically given once every 8 to 12 ...

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...

Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...

AbbVie ABBV announced positive top-line data from two phase III studies evaluating its psoriasis drug, Skyrizi (risankizumab) for a new indication — active psoriatic arthritis. Skyrizi is presently ...